Medical technology company Stryker (NYSE: SYK) met Wall Streets revenue expectations in Q3 CY2025, with sales up 10.2% year on year to $6.06 billion. Its non-GAAP profit of $3.19 per share was 1.9% above analysts’ consensus estimates.

Is now the time to buy SYK? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Stryker’s third quarter was marked by broad-based demand and resilient procedural volumes across its business segments, with management highlighting sustained organic sales growth and margin discipline. CEO Kevin Lobo attributed the results to strong performance in both Orthopedics and MedSurg & Neurotechnology, particularly emphasizing the impact of high Mako robotic system installations and robust growth in Trauma, Vascular, and Instruments. Lobo noted that “procedure volumes are very healthy, which affects, obviously, our implants as well as our small capital,” and pointed to a solid U.S. environment for both product and capital spending. Despite some lingering supply chain disruptions in the Medical segment, Stryker’s leadership cited strong execution and order books as key drivers for the quarter.

Looking forward, Stryker’s updated guidance rests on the expectation of continued procedural strength, a steady capital environment, and positive contributions from recently launched products and tuck-in acquisitions. Management described plans to leverage recent investments and product launches, such as the expanded Mako platform and new offerings in Vascular and Medical, to sustain growth. CFO Preston Wells cautioned that tariff headwinds will remain a meaningful offset to margin gains, but remains confident in the company’s ability to expand margins through operational improvements. Management is also focused on integrating recent acquisitions and anticipates that “international expansion, particularly for the Inari business, will begin to contribute more significantly in the second half of next year.”

Key Insights from Management’s Remarks

Management credited third quarter performance to robust orthopedic and MedSurg segment growth, continued procedural strength, and the successful integration of new product offerings and recent acquisitions.

• Orthopedics sustained above-market growth: Stryker’s U.S. Knee and Hip businesses maintained momentum due to high adoption of the Mako robotic-assisted surgical platform and the successful launch of new implant systems. CEO Kevin Lobo emphasized, “with every Mako that gets installed, we know there's going to be a high adoption of our products.”

• Trauma and Extremities outperformance: The Trauma and Extremities segment delivered strong double-digit growth, led by robust performance in Shoulder and Core Trauma products. Product innovations, such as the Pangea plating portfolio and Blueprint software, were cited as key enablers. Management noted upside potential in Foot and Ankle as an area for future improvement.

• Medical segment variance linked to supply chain: The Medical business faced ongoing supply chain challenges, particularly in emergency care. However, leadership maintained a positive full-year outlook, citing a strong order book and the expectation of accelerated growth in the fourth quarter, supported by recent launches like LIFEPAK 35 in Europe and continued momentum in Vocera’s communications solutions.

• Inari integration progressing well: Stryker reported successful onboarding of Inari’s sales team and strong procedural growth. The integration is expected to fuel double-digit pro forma sales growth for Inari, with management highlighting that international expansion will become more meaningful in the latter half of next year.

• Tuck-in acquisitions enhance portfolio: Two small acquisitions—Guard Medical’s NPseal negative pressure wound treatment and advanced medical balloons for the Sage business—were completed to reinforce Stryker’s product lineup. Management reiterated that M&A remains the company’s top capital allocation priority, with a healthy deal pipeline and capacity for larger transactions if value creation is clear.

Drivers of Future Performance

Stryker’s outlook is grounded in expectations for sustained procedure growth, ongoing product innovation, and margin expansion, while remaining vigilant to tariff impacts and supply chain risks.

• Procedure volumes and capital demand: Management anticipates continued healthy procedure volumes and a steady hospital capital expenditure environment, which should benefit sales of implants, robotics, and capital equipment. CEO Kevin Lobo stated that hospital balance sheets remain strong, noting a shift toward cash purchases for capital equipment like Mako.

• Tariffs and margin management: Ongoing tariffs are set to remain a material headwind, with CFO Preston Wells projecting a $200 million annual impact. Despite this, the company plans to offset headwinds through supply chain optimization, pricing initiatives, and disciplined spending to support margin expansion.

• Product launches and international expansion: Growth is expected from the rollout of new products—such as the expanded Mako software, Surpass Elite stent, and LIFEPAK 35—along with greater international contributions, especially as the Inari business leverages Stryker’s global infrastructure in the second half of next year.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will track (1) the pace of new product adoption, especially expanded Mako software and recently launched Vascular and Medical solutions; (2) the execution and international scaling of the Inari business, particularly as integration matures; and (3) ongoing margin management amid persistent tariff headwinds. Additional acquisitions and further supply chain normalization will also be important milestones for assessing Stryker’s ability to deliver on its growth and profitability targets.

Stryker currently trades at $368.98, in line with $369.01 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free for active Edge members).

High Quality Stocks for All Market Conditions

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.